Citations

Showing 10 of 108094 citations.

Life-Threatening Complications of Influenza vs Coronavirus Disease 2019 (COVID-19) in US Children
Halasa, Natasha , Young, Cameron C. , Newhams, Margaret M. , Nakamura, Mari , Levy, Emily R. , Soma, Vijaya L, Talj, Rana, Fitzgerald, Julie C. , Mack, Elizabeth H. , Schuster, Jennifer E. , Coates, Bria M. , Hall, Mark W. , Schwarz, Adam J. , Kong, Michele, Spinella, Philip C. , Loftis, Laura L. , McLaughlin, Gwenn E., Rowan, Courtney M. , Nofziger, Ryan A. , Babbitt, Christopher , Bowens, Cindy , Flori, Heidi R. , Gertz, Shira J. , Zinter, Matt S. , Hume, Janet R. , Singh, Aalok R. , Crandall, Hillary A, Cullimore, Melissa L. , Patel, Manish M. , Randolph, Adrienne G. , Influenza, for the Pediatric Intensive Care, Investigators, Overcoming COVID-19, Kong, Michele, Gaspers, Mary Glas , Sanders, Ronald C., Irby, Katherine , Peter, Mourani, Harvey, Helen , Osborne, Christina , Sara, Shankman, Mourani, Peter M. , Port, Emily, Van, Kevin A, Carroll, Christopher L. , Tarquinio, Keiko M. , Coates, Bria M, Wellnitz, Kari , Bhoojhawon, Guru , Sullivan, Janice E, Bradford, Tamara T. , Riggs, Becky J. , Randolph, Adrienne G, Chen, Sabrina R., Carroll, Ryan W. , Yager, Phoebe H. , Heidemann, Sabrina M. , Hume, Janet R, Martin, Lora , Malloch, Lacy , Inagaki, Kengo , Schuster, Jennifer E, Kietzman, Abigail , Clouser, Katharine N. , Kleinman, Lawrence C. , Horwitz, Steven M. , Keenaghan, Michael , Doymaz, Sule , Walker, Tracie C. , Hall, Mark W, Lansell, Amanda , Staat, Mary Allen , Carcillo, Joseph A. , Smallcomb, Laura , Halasa, Natasha B, Stewart, Laura S , Romero, Yesenia, Hayek, Haya , Bowens, Cindy, Maamari, Mia , Crandall, Hillary , Smith, Lincoln , Kong, Michele , Young, Cameron C , Randolph, Adrienne G , Levy, Emily R , Spinella, Philip C , Kong, Michele , Hume, Janet R , Staat, Mary A , Gertz, Shira J , Spieker, Andrew J. , Olson, Samantha M. , Amarin, Justin Z. , Moffitt, Kristin , Weiss, Scott L. , Maddux, Aline B. , Schwartz, Stephanie P. , Kong, Michele, Hobbs, Charlotte V. , Bembea, Melania M. , Giuliano, John S. , Cvijanovich, Natalie Z , Thomas, Neal J. , Influenza, for the Pediatric Intensive Care, Investigators, Overcoming COVID-19, Kong, Michele, Typpo, Katri , Michelson, Kelly Nicole , Coates, Bria M, Sullivan, Janice E, Montgomery, Vicki , Havlin, Kevin , Randolph, Adrienne G, Fernandes, Neil D. , Hume, Janet R, Dhanrajani, Anita D. , Schuster, Jennifer E, Hill, Shannon, McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , Dapul, Heda , Harwayne‐Gidansky, Ilana , Hymes, Saul , Hall, Mark W, Shein, Steven L. , Fink, Ericka L. , Halasa, Natasha B, Muñoz, Álvaro Coronado , Bowens, Cindy, McGuire, John K.

Mayo Clinic

Clinical Infectious Diseases | June 19, 2022 | Volume: 76 | Issue: 3 | Pages: e280-e290

10.1093/cid/ciac477 | PMID 35717646 Get It

Abstract Background Clinical differences between critical illness from influenza infection vs coronavirus disease 2019 (COVID-19) have not been well characterized in pediatric patients. Methods We compared demographics, clinical characteristics, and outcomes of US children (aged 8 months to 17 years) admitted to the intensive care or high-acuity unit with influenza or COVID-19. Using mixed-effects models, we assessed the odds of death or requiring life support for influenza vs COVID-19 after adjustment for age, sex, race and Hispanic origin, and underlying conditions including obesity. Results Children with influenza (n = 179) were younger than those with COVID-19 (n = 381; median, 5.2 years vs 13.8 years), less likely to be non-Hispanic Black (14.5% vs 27.6%) or Hispanic (24.0% vs 36.2%), and less likely to have ≥1 underlying condition (66.4% vs 78.5%) or be obese (21.4% vs 42.2%), and a shorter hospital stay (median, 5 days vs 7 days). They were similarly likely to require invasive mechanical ventilation (both 30.2%), vasopressor support (19.6% and 19.9%), or extracorporeal membrane oxygenation (2.2% and 2.9%). Four children with influenza (2.2%) and 11 children with COVID-19 (2.9%) died. The odds of death or requiring life support in children with influenza vs COVID-19 were similar (adjusted odds ratio, 1.30; 95% confidence interval, .78–2.15; P = .32). Conclusions Despite differences in demographics and clinical characteristics of children with influenza or COVID-19, the frequency of life-threatening complications was similar. Our findings highlight the importance of implementing prevention measures to reduce transmission and disease severity of influenza and COVID-19.
Controversies in the Management of Central Nervous System Coccidioidomycosis
Ampel, Neil M. , Blair, Janis E. , Donovan, Fariba , Fierer, Joshua , Galgiani, John N. , Heidari, Arash , Johnson, Royce H. , Shatsky, Stanley A., Uchiyama, Christopher M. , Stevens, David A. , Thompson, George R

Mayo Clinic

Clinical Infectious Diseases | June 19, 2022 | Volume: 75 | Issue: 4 | Pages: 555-559

10.1093/cid/ciac478 | PMID 35717645 Get It

Abstract Central nervous system infection with Coccidioides spp. is fatal if untreated and complications occur even when therapy is directed by experienced clinicians. We convened a panel of clinicians experienced in the management of coccidioidal meningitis to summarize current controversies and provide consensus for the management of this difficult infection.
Moving beyond the vasodilator model in heart failure with reduced ejection fraction – lessons from sildenafil
Reddy, Yogesh N.V. , Nishimura, Rick

Mayo Clinic

European Journal of Heart Failure | June 19, 2022 | Volume: 24 | Issue: 7 | Pages: 1249-1252

10.1002/ejhf.2582 | PMID 35717600 Get It

Ischiofemoral impingement syndrome provoked by labor: An unusual case of complete sciatic mononeuropathy
Saw, Jacqui‐Lyn , Hale, Jeremy, Madhavan, Ajay A. , Ringler, Michael D. , Toledano, Michel , Madhavan, Ajay A , Hale, Jeremy, Naddaf, Elie

Mayo Clinic

The Neuroradiology Journal | June 19, 2022 | Volume: 36 | Issue: 1 | Pages: 116-118

10.1177/19714009221109895 | PMID 35723073 Get It

Peripheral neuropathies are a recognized complication of labor in the post-partum period. Herein, we describe an uncommon presentation of sciatic mononeuropathy due to ischiofemoral impingement during labor. A 29-year-old, gravida 4 para 2, female presented post-partum with acute left lower limb paresthesia and left foot drop, following spontaneous vaginal delivery of twins. Neurological examination demonstrated no activation of the left sciatic-innervated muscles and sensory loss in the same distribution. Electromyography (EMG) demonstrated an acute complete left sciatic mononeuropathy. MRI of the lumbosacral plexus and sciatic nerve showed a narrowed quadratus femoris space with mild edema of the muscle, consistent with ischiofemoral impingement syndrome. In addition, there was flattening of the sciatic nerve as it passed through the ischiofemoral space. She was treated conservatively, and at 7-month follow-up, there was marked improvement in muscle strength with ongoing sensory impairment. Repeat EMG demonstrated reinnervation in all sciatic-innervated muscles. This case highlights the risk of a sciatic mononeuropathy secondary to ischiofemoral impingement in the peripartum setting. Future studies are needed to determine if women with a narrow ischiofemoral space at baseline are at increased risk for peripheral nerve injury during labor.
Abstract A19: Aspirin use and ovarian cancer risk by lymphocyte infiltration
Hecht, Jonathan L. , Goode, Ellen L. , Sasamoto, Naoko , Barnard, Mollie , Trabert, Britton , Terry, Kathryn L. , Tworoger, Shelley S.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 18, 2022 | Volume: 29 | Issue: 9_Supplement | Pages: A19-A19

10.1158/1538-7755.modpop19-a19 Get It

Abstract Introduction: There is growing evidence to support a modest inverse association between daily aspirin use and ovarian cancer risk. We previously hypothesized that this association may differ by immune cell infiltration. In our prior study evaluating heterogeneity by tumor-associated macrophage (TAM) infiltration, aspirin use was associated with lower risk of ovarian cancer with high protumorigenic M2-type TAM infiltration, but not low M2-type TAM infiltration. The goal of the present study was to evaluate the hypothesis that the association between aspirin use and ovarian cancer risk also differs by infiltration with tumor-infiltrating lymphocytes (TILs). Methods: We included cases and matched controls from the Nurses’ Health Study (NHS), NHSII, and New England Case Control Study. Study participants self-reported aspirin use including regular use (≥1 x per week), duration of use, and number of tablets. A gynecologic pathologist (JLH), who was blinded to exposure status, reviewed hematoxylin and eosin stained tumor slides to quantify TILs for all cases (n=547). We used polytomous logistic regression, adjusted for ovarian cancer risk factors, to estimate odds ratios (OR) for aspirin use and ovarian cancer risk by TIL infiltration. Results: Overall, recent aspirin use was associated with lower risk of ovarian cancer compared with no regular aspirin use (OR=0.65, 95%CI=0.47-0.89). Recent aspirin use was associated with a lower risk of ovarian cancer exhibiting TIL infiltration (OR=0.38, 95%CI=0.26-0.56) but not with TIL-negative cancers (OR=1.00, 95%CI=0.71-1.41; p-heterogeneity <0.001). We observed similar results for aspirin duration and tablets. For duration, comparing ≥10 years of aspirin use to <1 year we observed a significantly lower risk of ovarian cancer with TILs (OR=0.47, 95%CI=0.41-0.71; p-trend=0.004), but a nonsignificant reduction for ovarian cancer without TILs (OR=0.86, 95%CI=0.59-1.26; p-trend=0.72; p-heterogeneity=0.03). Comparing ≥6 tablets to <1 tablet per week, there was evidence of a lower risk of ovarian cancer with TILs (OR=0.47, 95%CI=0.30-0.75; p-trend=0.001) but not without TILs (OR=1.02, 95%CI=0.70-1.48; p-trend=0.84; p-heterogeneity=0.003). Conclusions: Our results suggest that prediagnosis aspirin use may be an important modulator of immune cell infiltration in ovarian tumors, supporting an immunogenic mechanism for aspirin in ovarian carcinogenesis. Further work is under way to evaluate nonaspirin nonsteroidal anti-inflammatory drugs, and to consider which subsets of TAMs and TILs may be driving heterogeneity in the associations between anti-inflammatory drugs and ovarian cancer risk. Citation Format: Mollie E. Barnard, Britton Trabert, Jonathan L. Hecht, Ellen L. Goode, Naoko Sasamoto, Kathryn L. Terry, Shelley S. Tworoger. Aspirin use and ovarian cancer risk by lymphocyte infiltration [abstract]. In: Proceedings of the AACR Special Conference on Modernizing Population Sciences in the Digital Age; 2019 Feb 19-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(9 Suppl):Abstract nr A19.
Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays: Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers
Aakre, Kristin M. , Saenger, Amy K., Body, Richard , Collinson, Paul , Hammarsten, Ola , Jaffe, Allan S. , Kavsak, Peter A. , Omland, Torbjørn , Ordonez-Lianos, Jordi, Apple, Fred S. , Body, Rick , Collinson, Paul O , Aakre, Kristin M , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | June 18, 2022 | Volume: 68 | Issue: 8 | Pages: 1022-1030

10.1093/clinchem/hvac092 | PMID 35716089 Get It

Abstract The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers provides evidence-based educational documents to facilitate uniform interpretation and utilization of cardiac biomarkers in clinical laboratories and practice. The committee’s goals are to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay in clinical practice. Measurement of high-sensitivity cardiac troponin (hs-cTn) assays is a cornerstone in the clinical evaluation of patients with symptoms and/or signs of acute cardiac ischemia. To define myocardial infarction, the Universal Definition of Myocardial Infarction requires patients who manifest with features suggestive of acute myocardial ischemia to have at least one cTn concentration above the sex-specific 99th percentile upper reference limit (URL) for hs-cTn assays and a dynamic pattern of cTn concentrations to fulfill the diagnostic criteria for MI. This special report provides an overview of how hs-cTn 99th percentile URLs should be established, including recommendations about prescreening and the number of individuals required in the reference cohort, how statistical analysis should be conducted, optimal preanalytical and analytical protocols, and analytical/biological interferences or confounds that can affect accurate determination of the 99th percentile URLs. This document also provides guidance and solutions to many of the issues posed.
Hepatology Highlights
Povero, Davide , Ahn, Joseph , Arnold, Jorge , Ahn, Joseph C , Udompap, Prowpanga , Ilyas, Sumera I. , Arab, Juan Pablo

Mayo Clinic

Hepatology | June 18, 2022 | Volume: 76 | Issue: 1 | Pages: 1-2

10.1002/hep.32567 Get It

ALG8‐CDG: Molecular and phenotypic expansion suggests clinical management guidelines
Albokhari, Daniah , Guberinic, Alis, Daniel, Earnest James Paul , Engelhardt, Nicole , Fiumara, Agata , Trimarchi, Gabriele , Wolfe, Lynne A. , Raymond, Kimiyo , He, Miao , Lam, Christina , Edmondson, Andrew C. , Raymond, Kimiyo M, Edmondson, Andrew C , Engelhardt, Nicole M , Ng, Bobby G. , Barone, Rita , Garavelli, Livia , Morava, Éva , Freeze, Hudson H.

Mayo Clinic

Journal of Inherited Metabolic Disease | June 18, 2022 | Volume: 45 | Issue: 5 | Pages: 969-980

10.1002/jimd.12527 | PMID 35716054 Get It

AbstractCongenital disorders of glycosylation are a continuously expanding group of monogenic disorders of glycoprotein and glycolipid glycan biosynthesis. These disorders mostly manifest with multisystem involvement. Individuals with ALG8‐CDG commonly present with hypotonia, protein‐losing enteropathy, and hepatic involvement. Here, we describe seven unreported individuals diagnosed with ALG8‐CDG based on biochemical and molecular testing and we identify nine novel variants in ALG8, bringing the total to 26 individuals with ALG8‐CDG in the medical literature. In addition to the typical multisystem involvement documented in ALG8‐CDG, our cohort includes the two oldest patients reported and further expands the phenotype of ALG8‐CDG to include stable intellectual disability, autism spectrum disorder and other neuropsychiatric symptoms. We further expand the clinical features in a variety of organ systems including ocular, musculoskeletal, dermatologic, endocrine, and cardiac abnormalities and suggest a comprehensive evaluation and monitoring strategy to improve clinical management.
Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer
Seneviratne, Danushka S. , Advani, Pooja , Chumsri, Saranya , Beltran, Chris , Bush, Aaron , Vallow, Laura A., Seneviratne, Danushka , Bush, Aaron F, Beltran, Chris J , Trifiletti, Daniel M.

Mayo Clinic

Cancers | June 18, 2022 | Volume: 14 | Issue: 12 | Pages: 3009

10.3390/cancers14123009 | PMID 35740674 Get It

BNCT is a high LET radiation therapy modality that allows for biologically targeted radiation delivery to tumors while reducing normal tissue impacts. Although the clinical use of BNCT has largely been limited to phase I/II trials and has primarily focused on difficult-to-treat malignancies such as recurrent head and neck cancer and recurrent gliomas, recently there has been a renewed interest in expanding the use of BNCT to other disease sites, including breast cancer. Given its high LET characteristics, its biologically targeted and tumor specific nature, as well as its potential for use in complex treatment settings including reirradiation and widespread metastatic disease, BNCT offers several unique advantages over traditional external beam radiation therapy. The two main boron compounds investigated to date in BNCT clinical trials are BSH and BPA. Of these, BPA in particular shows promise in breast cancer given that is taken up by the LAT-1 amino acid transporter that is highly overexpressed in breast cancer cells. As the efficacy of BNCT is directly dependent on the extent of boron accumulation in tumors, extensive preclinical efforts to develop novel boron delivery agents have been undertaken in recent years. Preclinical studies have shown promise in antibody linked boron compounds targeting ER/HER2 receptors, boron encapsulating liposomes, and nanoparticle-based boron delivery systems. This review aims to summarize the physical and biological basis of BNCT, the preclinical and limited clinical data available to date, and discuss its potential to be utilized for the successful treatment of various breast cancer disease states.
Major adverse cardiovascular events after diagnosis of myocardial injury and types 1 and 2 myocardial infarction
Knott, Jonathan D , Ola, Olatunde , Akula, Ashok , Mehta, Ramila A. , Dworak, Marshall , Crockford, Erika, Lobo, Ronstan , Rastas, Nicholas, Karturi, Swetha, Wohlrab, Scott, Hodge, David O. , Grube, Eric , Tak, Tahir , Cagin, Charles , Gulati, Rajiv , Jaffe, Allan S. , Sandoval, Yader , Sandoval, Yader , Michieli, Laura De , Grube, Eric, Jaffe, Allan S.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | June 18, 2022 | Volume: 11 | Issue: 7 | Pages: 546-557

10.1093/ehjacc/zuac075 | PMID 35715942 Get It

Abstract Aims Limited US outcome data exist among patients with myocardial injury and types 1 and 2 myocardial infarction (MI) evaluated with high-sensitivity cardiac troponin (hs-cTn). Methods and results This is an observational US cohort study of emergency department (ED) patients undergoing hs-cTnT measurement. Cases with ≥1 hs-cTnT increase >99th percentile were adjudicated following the Fourth Universal Definition of MI. Post-discharge major adverse cardiovascular events (MACE) included death, MI, heart failure (HF) hospitalization, stroke or transient ischaemic attack, and new-onset atrial fibrillation or flutter during 2 years follow-up. Among 2002 patients, 857 (43%) had ≥1 hs-cTnT >99th percentile. Among these, 702 (81.9%) had myocardial injury, 64 (7.5%) had type 1 MI, and 91 (10.6%) had type 2 MI. Compared with patients without myocardial injury, type 2 MI [8.4 vs. 50%; adjusted hazard ratio (HR) 2.31, 95% confidence interval (CI) 1.49–3.58] and myocardial injury (8.4 vs. 47%; adjusted HR 3.13, 95% CI 2.39–4.09) had a higher risk of MACE, in large part because of death and HF hospitalizations. Compared with patients with type 1 MI, type 2 MI (23 vs. 50%; adjusted HR 2.24; 95% CI 1.23–4.10) and myocardial injury (23 vs. 47%; adjusted HR 2.02; 95% CI 1.20–3.40) also have a higher risk of MACE. Conclusion Among unselected US ED patients undergoing hs-cTnT measurement, most increases are due to myocardial injury, and type 2 MI is more frequent than type 1 MI. Patients with myocardial injury and type 2 MI have morbid outcomes, in large part due to death and HF.